Shares of Evotec AG (NASDAQ:EVO – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the four research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and three have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $7.00.
Several equities research analysts have weighed in on the company. TD Cowen cut Evotec from a “buy” rating to a “hold” rating in a research note on Wednesday. Wall Street Zen cut Evotec from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings upgraded Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, April 24th. Finally, HC Wainwright began coverage on Evotec in a research note on Wednesday, April 15th. They issued a “buy” rating and a $7.00 price objective on the stock.
Get Our Latest Research Report on Evotec
Evotec Stock Down 11.9%
Evotec (NASDAQ:EVO – Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.05 earnings per share (EPS) for the quarter. Evotec had a negative net margin of 26.20% and a negative return on equity of 24.93%. The business had revenue of $297.02 million for the quarter. On average, sell-side analysts forecast that Evotec will post -0.63 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP increased its position in Evotec by 25.7% during the 4th quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company’s stock worth $5,536,000 after purchasing an additional 367,545 shares in the last quarter. WCM Investment Management LLC lifted its stake in Evotec by 12.1% in the 1st quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock valued at $1,480,000 after purchasing an additional 67,917 shares during the last quarter. ABC Arbitrage SA boosted its position in Evotec by 319.7% in the fourth quarter. ABC Arbitrage SA now owns 554,287 shares of the company’s stock valued at $1,707,000 after buying an additional 422,230 shares in the last quarter. Optiver Holding B.V. grew its stake in shares of Evotec by 598.4% during the first quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock worth $709,000 after buying an additional 242,973 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Evotec during the fourth quarter worth $565,000. Institutional investors own 5.81% of the company’s stock.
About Evotec
Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.
Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.
Featured Articles
- Five stocks we like better than Evotec
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
